Type 1 diabetes
Drug research and approvals for type 1 diabetes: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 430 studies of type 1 diabetes are recruiting on ClinicalTrials.gov, Health Canada has authorized 84 drug trials for it since 2013, FDA has 4 approved and 11 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 430
- Trials authorized in Canada: 84
- FDA orphan approvals: 4
- EU medicines: 1
- Study to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 DiabetesNCT07951658 · Phase 1 · Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · starts Sep 27, 2026
- AI-Assisted Diabetes Education for Children With Type 1 DiabetesNCT07946770 · Not applicable · Yuzuncu Yil University · starts Mar 10, 2026
- Silica-Based Wound Treatment (Curi01) Plus Standard Care Versus Standard Care Alone for Chronic Diabetic Foot WoundsNCT07937215 · Not applicable · Cutempa Medical AG · starts Aug 20, 2026
- Differentiating Heart Disease Between Adult-onset Autoimmune and Type 2 DiabetesNCT07911007 · Not applicable · University of Roma La Sapienza · starts Jun 20, 2024
- Continuous Monitoring of Plantar Temperature Variations Using Connected Insoles and a Mobile Application for Diabetic…NCT07910721 · Not applicable · Solsius · starts Mar 10, 2026
- A Research Study to Check the Safety of NNC9836-0001 When Given to Healthy Participants and Participants With Type 2…NCT07896109 · Phase 1 · Novo Nordisk A/S · starts Oct 22, 2026
- Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity.NCT07891156 · Phase 2 / Phase 3 · McGill University Health Centre/Research Institute of the McGill University Health Centre · starts Oct 13, 2026
- RIGHTEST iFree 2 CGM in Pregnant Women With Diabetes StudyNCT07889388 · Not applicable · Bionime Corporation · starts Jun 9, 2026
- A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 DiabetesNCT07881887 · Phase 1 · Eli Lilly and Company · starts Oct 22, 2026
How its trials ended
3,244 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 739 whose ending is known, 56% met their primary endpoint, 7% missed it and 37% stopped early.
- Completed, result not reported1,67252%
- Ongoing54617%
- Met its primary endpoint41313%
- Status unknown2879%
- Stopped: other or unclear1715%
- Missed its primary endpoint502%
- Stopped: enrollment or feasibility481%
- Stopped: sponsor or business decision221%
- Stopped: lack of efficacy211%
- Stopped: funding12<1%
- Stopped: safety2<1%
| Jul 15, 2026 | A phase 1/2, first-in-human, dose escalation and expansion study to evaluate the safety, tolerability, and efficacy of VV-14300 (adeno-associated virus…VV-14300 / Actemra / Avtozma / Tyenne | Kriya Therapeutics | Ongoing |
| May 20, 2026 | Changes to body composition with semaglutide vs. placebo in adults with type 1 diabetes and overweight/obesity: a double-blinded, randomized, parallel…Wegovy | Research Institute of The McGill University Health Centre | Pending |
| Dec 19, 2025 | Fully closed loop glucose control in adults with type 1 diabetes using tirzepatide: a randomized, multi-center, open-label, non-inferiority, parallel trial.Tirzepatide | Research Institute of The McGill University Health Centre | Pending |
| Nov 26, 2025 | A phase 3, double-blind, randomized, placebo-controlled study of baricitinib to preserve beta cell function in participants newly diagnosed with type 1…Baricitinib (LY3009104) | Eli Lilly | Ongoing |
| Oct 23, 2025 | A phase 3, double-blind, randomized, placebo-controlled study of baricitinib to delay stage 3 type 1 diabetes in at-risk participants aged =1 to <36 years…Baricitinib (LY3009104) | Eli Lilly | Ongoing |
| Aug 15, 2025 | A randomized, double-blind, phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with…Tzield (teplizumab (SAR446681)) | Sanofi-Aventis Canada Inc | Ongoing |
| May 29, 2025 | A 26-week study comparing the efficacy and safety of once-weekly insulin icodec and once-daily insulin glargine U100, both in combination with insulin aspart,…Insulin icodec | Novo Nordisk | Ongoing |
| Mar 20, 2025 | A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy and long-term safety of tirzepatide once…Tirzepatide (LY3298176) | Eli Lilly | Ongoing |
| Feb 11, 2025 | A study to assess the pharmacodynamics, pharmacokinetics, and tolerability of XRS-0104 (glucagon) injectionGlucagon (XRS-0104) | Beta Bionics | Closed |
| Jan 8, 2025 | Jak inhibitors to preserve c-peptide production in new onset T1D: a phase 2 multi-center, randomized, double-blind, placebo-controlled study to evaluate the…Abrocitinib (PF-04965842) / Ritlecitinib (PF-06651600) | The Hospital for Sick Children | Ongoing |
| Jun 12, 2026 | TzieldTo delay the decline in endogenous insulin production in pediatric patients aged 8 to 17 years recently diagnosed with Stage 3 type 1… | Provention Bio, Inc. | Approved |
| Apr 20, 2026 | TzieldTo delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients 1 year of age and older with Stage 2 type 1 diabetes | Provention Bio, Inc. | Approved |
| Jun 28, 2023 | LantidraTreatment of adults with Type 1 diabetes who are unable to approach target HbA1c because of current repeated episodes of severe… | CellTrans Inc. | Approved |
| Nov 17, 2022 | TzieldTo delay the onset of Stage 3 type 1 diabetes in adults and pediatric patients 8 years of age and older with Stage 2 type 1 diabetes | Provention Bio, Inc. | Approved |
| Mar 9, 2020 | Purified Human Allogeneic Pancreatic Islets of LangerhansTreatment of Brittle Type 1 Diabetes | University of Minnesota | Designated |
| Jul 22, 2019 | Allogeneic Human Pancreatic Islets of LangerhansTreatment of Brittle Type 1 Diabetes | Hospital of the University of Pennsylvania (Penn Medicine) | Designated |
| Jun 4, 2019 | Allogeneic Human Pancreatic Islets of LangerhansTreatment of Brittle Type 1 Diabetes | University of California, San Francico | Designated |
| May 1, 2019 | Allogeniec Human Pancreatic Islets of LangerhansTreatment of brittle type 1 diabetes | Diabetes Research Institute & Cell Transplant Center, Univ of Miami | Designated |
| May 1, 2019 | Purified Allogeneic Human Pancreatic Islets of LangerhansTreatment of Brittle Type 1 Diabetes | University of Chicago | Designated |
| Jan 12, 2017 | MethyldopaTreatment of type 1 diabetes in DQ8 positive patients with residual beta cell function | IM Therapeutics LLC | Designated |
| Mar 3, 2015 | alpha1-proteinase inhibitor (human)Treatment of Type 1 diabetes mellitus patients with residual beta-cell function. | Grifols Therapeutics, Inc. | Designated |
| Dec 20, 2013 | CD40/CD80/CD86 modified autologous dendritic cell therapyTreatment Type 1 diabetes mellitus patients with residual beta cell function | DiaVacs, Inc. | Designated |
| May 30, 2013 | AbataceptTreatment of type 1 diabetes mellitus patients with residual beta cell function | Orban Biotech LLC | Designated |
| Feb 11, 2013 | Human insulin beta chain peptide with incomplete Freund's…Treatment of Type 1 diabetes patients with residual beta cell function | Orban Biotech, LLC | Designated |
| Apr 30, 2010 | Ex-vivo cultered adult human mesenchymal stem cellsTreatment of Type 1 diabetes patients with residual beta cell function | Mesoblast, Inc. | Designated |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Jan 8, 2026 | TeizeildTeplizumab | Sanofi Winthrop Industrie | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA